Cargando…
Brivaracetam in the treatment of epilepsy: a review of clinical trial data
Brivaracetam (BRV), an analog of levetiracetam (LEV), was discovered during a target-based rational drug discovery program that aimed to identify potent synaptic vesicle protein 2A (SV2A) ligands. Among the 12,000 compounds screened in vitro, BRV was found to have 15–30 times greater affinity for SV...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6750854/ https://www.ncbi.nlm.nih.gov/pubmed/31571877 http://dx.doi.org/10.2147/NDT.S143548 |